Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance

Immunity

Volumn 19, Issue 4, 2003, Pages 503-514

  Zheng, Xin Xiao ^a   Sánchez Fueyo, Alberto ^a   Sho, Masayuki ^b   Domenig, Christoph ^a   Sayegh, Mohamed H ^b   Strom, Terry B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 15 RECEPTOR ANTIBODY; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; RAPAMYCIN; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; GRAFT REJECTION; IMMUNOREGULATION; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE;

EID: 10744228165     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(03)00259-0     Document Type: Article

References (49)

1. Adachi M., Sekiya M., Torigoe T., Takayama S., Reed J.C., Miyazaki T., Minami Y., Taniguchi T., Imai K. Interleukin-2 (IL-2) upregulates BAG-1 gene expression through serine-rich region within IL-2 receptor beta c chain. Blood. 88:1996;4118-4123.
2. Banz A., Pontoux C., Papiernik M. Modulation of Fas-dependent apoptosis. a dynamic process controlling both the persistence and death of CD4 regulatory T cells and effector T cells J. Immunol. 169:2002;750-757.
3. Bierer B.E., Mattila P.S., Standaert R.F., Herzenberg L.A., Burakoff S.J., Crabtree G., Schreiber S.L. Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc. Natl. Acad. Sci. USA. 87:1990;9231-9235.
4. Boise L.H., Minn A.J., Noel P.J., June C.H., Accavitti M.A., Lindsten T., Thompson C.B. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 3:1995;87-98.
5. Cobbold S., Waldmann H. Infectious tolerance. Curr. Opin. Immunol. 10:1998;518-524.
6. Dai Z., Konieczny B.T., Baddoura F.K., Lakkis F.G. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J. Immunol. 161:1998;1659-1663.
7. Dai Z., Arakelov A., Wagener M., Konieczny B.T., Lakkis F.G. The role of the common cytokine receptor gamma-chain in regulating IL-2-dependent, activation-induced CD8+ T cell death. J. Immunol. 163:1999;3131-3137.
8. Faust A., Rothe H., Schade U., Lampeter E., Kolb H. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10. Transplantation. 62:1996;648-652.
9. Ferrari-Lacraz S., Zheng X.X., Kim Y.S., Li Y., Maslinski W., Li X.C., Strom T.B. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J. Immunol. 167:2001;3478-3485.
10. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:2003;330-336.
11. Furtado G.C., De Lafaille M.A., Kutchukhidze N., Lafaille J.J. Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 196:2002;851-857.
12. Graca L., Thompson S., Lin C.Y., Adams E., Cobbold S.P., Waldmann H. Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J. Immunol. 168:2002;5558-5565.
13. Hall B.M., Pearce N.W., Gurley K.E., Dorsch S.E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action. J. Exp. Med. 171:1990;141-157.
14. Hara M., Kingsley C.I., Niimi M., Read S., Turvey S.E., Bushell A.R., Morris P.J., Powrie F., Wood K.J. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J. Immunol. 166:2001;3789-3796.
15. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:2003;1057-1061.
16. Kim Y.S., Maslinski W., Zheng X.X., Stevens A.C., Li X.C., Tesch G.H., Kelley V.R., Strom T.B. Targeting the IL-15 receptor with an antagonist IL-15 mutant/Fc gamma2a protein blocks delayed-type hypersensitivity. J. Immunol. 160:1998;5742-5748.
17. Kingsley C.I., Karim M., Bushell A.R., Wood K.J. CD25+CD4+ regulatory T cells prevent graft rejection. CTLA-4- and IL-10-dependent immunoregulation of alloresponses J. Immunol. 168:2002;1080-1086.
18. Kishimoto K., Dong V.M., Issazadeh S., Fedoseyeva E.V., Waaga A.M., Yamada A., Sho M., Benichou G., Auchincloss H. Jr., Grusby M.J.et al. The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J. Clin. Invest. 106:2000;63-72.
19. Kneitz B., Herrmann T., Yonehara S., Schimpl A. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 25:1995;2572-2577.
20. Lenardo M.J. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature. 353:1991;858-861.
21. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5:1999;1298-1302.
22. Li X.C., Demirci G., Ferrari-Lacraz S., Groves C., Coyle A., Malek T.R., Strom T.B. IL-15 and IL-2. a matter of life and death for T cells in vivo Nat. Med. 7:2001;114-118.
23. Lindahl K.F., Wilson D.B. Histocompatibility antigen-activated cytotoxic T lymphocytes. I. Estimates of the absolute frequency of killer cells generated in vitro. J. Exp. Med. 145:1977;500-507. a.
24. Lindahl K.F., Wilson D.B. Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J. Exp. Med. 145:1977;508-522. b.
25. Lipman M.L., Stevens A.C., Bleackley R.C., Helderman J.H., McCune T.R., Harmon W.E., Shapiro M.E., Rosen S., Strom T.B. The strong correlation of cytotoxic T lymphocyte-specific serine protease gene transcripts with renal allograft rejection. Transplantation. 53:1992;73-79.
26. Lipman M.L., Stevens A.C., Strom T.B. Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J. Immunol. 152:1994;5120-5127.
27. Maki T., Ichikawa T., Blanco R., Porter J. Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. Proc. Natl. Acad. Sci. USA. 89:1992;3434-3438.
28. Malek T.R., Yu A., Vincek V., Scibelli P., Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rβ-deficient mice. Implications for the nonredundant function of IL-. 2.(Immunity 17):2002;167-178.
29. Markees T.G., Serreze D.V., Phillips N.E., Sorli C.H., Gordon E.J., Shultz L.D., Noelle R.J., Woda B.A., Greiner D.L., Mordes J.P., Rossini A.A. NOD mice have a generalized defect in their response to transplantation tolerance induction. Diabetes. 48:1999;967-974.
30. Marrack P., Bender J., Hildeman D., Jordan M., Mitchell T., Murakami M., Sakamoto A., Schaefer B.C., Swanson B., Kappler J. Homeostasis of alpha beta TCR+ T cells. Nat. Immunol. 1:2000;107-111.
31. Noorchashm H., Moore D.J., Noto L.E., Noorchashm N., Reed A.J., Reed A.L., Song H.K., Mozaffari R., Jevnikar A.M., Barker C.F., Naji A. Impaired CD4 T cell activation due to reliance upon B cell-mediated costimulation in nonobese diabetic (NOD) mice. J. Immunol. 165:2000;4685-4696.
32. Papiernik M., do Carmo Leite-de-Moraes M., Pontoux C., Joret A.M., Rocha B., Penit C., Dy M. T cell deletion induced by chronic infection with mouse mammary tumor virus spares a CD25-positive, IL-10-producing T cell population with infectious capacity. J. Immunol. 158:1997;4642-4653.
33. Papiernik M., de Moraes M.L., Pontoux C., Vasseur F., Penit C. Regulatory CD4 T cells. expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency Int. Immunol. 10:1998;371-378.
34. Rabinovitch A., Suarez-Pinzon W.L., Shapiro A.M., Rajotte R.V., Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes. 51:2002;638-645.
35. Renno T., Attinger A., Locatelli S., Bakker T., Vacheron S., MacDonald H.R. Cutting edge. apoptosis of superantigen-activated T cells occurs preferentially after a discrete number of cell divisions in vivo J. Immunol. 162:1999;6312-6315.
36. Sanchez-Fueyo A., Weber M., Domenig C., Strom T.B., Zheng X.X. Tracking the immunoregulatory mechanisms active during allograft tolerance. J. Immunol. 168:2002;2274-2281.
37. Steiger J., Nickerson P.W., Steurer W., Moscovitch-Lopatin M., Strom T.B. IL-2 knockout recipient mice reject islet cell allografts. J. Immunol. 155:1995;489-498.
38. Steurer W., Nickerson P.W., Steele A.W., Steiger J., Zheng X.X., Strom T.B. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J. Immunol. 155:1995;1165-1174.
39. Suchin E.J., Langmuir P.B., Palmer E., Sayegh M.H., Wells A.D., Turka L.A. Quantifying the frequency of alloreactive T cells in vivo. new answers to an old question J. Immunol. 166:2001;973-981.
40. Taylor P.A., Noelle R.J., Blazar B.R. CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193:2001;1311-1318.
41. Teh H.S., Harley E., Phillips R.A., Miller R.G. Quantitative studies on the precursors of cytotoxic lymphocytes. I. Characterization of a clonal assay and determination of the size of clones derived from single precursors. J. Immunol. 118:1977;1049-1056.
42. Van Parijs L., Refaeli Y., Lord J.D., Nelson B.H., Abbas A.K., Baltimore D. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity. 11:1999;281-288.
43. Waldmann T.A., Dubois S., Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes. implications for immunotherapy Immunity. 14:2001;105-110.
44. Walker L.S., Chodos A., Eggena M., Dooms H., Abbas A.K. Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J. Exp. Med. 198:2003;249-258.
45. Wells A.D., Gudmundsdottir H., Turka L.A. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD. 28(differentially regulate the induction and duration of a proliferative response. J. Clin. Invest. 100):1997;3173-3183.
46. Wells A.D., Li X.C., Li Y., Walsh M.C., Zheng X.X., Wu Z., Nunez G., Tang A., Sayegh M., Hancock W.W.et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5:1999;1303-1307.
47. Wells A.D., Walsh M.C., Bluestone J.A., Turka L.A. Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy. J. Clin. Invest. 108:2001;895-903.
48. Zelenika D., Adams E., Humm S., Graca L., Thompson S., Cobbold S.P., Waldmann H. Regulatory T cells overexpress a subset of Th2 gene transcripts. J. Immunol. 168:2002;1069-1079.
49. Zheng X.X., Steele A.W., Hancock W.W., Kawamoto K., Li X.C., Nickerson P.W., Li Y., Tian Y., Strom T.B. IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 163:1999;4041-4048.